-+ 0.00%
-+ 0.00%
-+ 0.00%

Kangchen Pharmaceutical (603590.SH): The KC1086 project was approved by the FDA to conduct clinical trials

Zhitongcaijing·12/24/2025 09:49:02
Listen to the news

Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) issued an announcement. Recently, the company obtained the “Notice of Continuing Clinical Research” issued by the US Food and Drug Administration (FDA), and the KC1086 tablet clinical trial application submitted by the company was officially approved by the FDA.

KC1086 is a potent and highly selective small molecule inhibitor of Lysine Acetyltransferase 6 (KAT6) with a novel structure completely independently developed by the company. It is intended for the treatment of advanced recurrent or metastatic solid tumors.